期刊
SCANDINAVIAN JOURNAL OF IMMUNOLOGY
卷 94, 期 5, 页码 -出版社
WILEY
DOI: 10.1111/sji.13101
关键词
autoimmunity; Coronavirus disease-19; COVID-19; COVID-19 vaccination; immunomodulation; intravenous immunoglobulin; Long-COVID; Post-COVID
类别
The coronavirus disease-19 (COVID-19) pandemic caused by SARS-CoV-2 presents challenges globally, with a small percentage of patients progressing to severe or fatal involvement of multiple organs. Intravenous immunoglobulin (IVIg) treatment has shown benefits in reducing ICU stays, lowering mortality rates, and improving pulmonary function in critically ill patients with COVID-19.
The coronavirus disease-19 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) challenged globally with its morbidity and mortality. A small percentage of affected patients (20%) progress into the second stage of the disease clinically presenting with severe or fatal involvement of lung, heart and vascular system, all contributing to multiple-organ failure. The so-called 'cytokines storm' is considered the pathogenic basis of severe disease and it is a target for treatment with corticosteroids, immunotherapies and intravenous immunoglobulin (IVIg). We provide an overview of the role of IVIg in the therapy of adult patients with COVID-19 disease. After discussing the possible underlying mechanisms of IVIg immunomodulation in COVID-19 disease, we review the studies in which IVIg was employed. Considering the latest evidence that show a link between new coronavirus and autoimmunity, we also discuss the use of IVIg in COVID-19 and anti-SARS-CoV-2 vaccination related autoimmune diseases and the post-COVID-19 syndrome. The benefit of high-dose IVIg is evident in almost all studies with a rapid response, a reduction in mortality and improved pulmonary function in critically ill COVID-19 patients. It seems that an early administration of IVIg is crucial for a successful outcome. Studies' limitations are represented by the small number of patients, the lack of control groups in some and the heterogeneity of included patients. IVIg treatment can reduce the stay in ICU and the demand for mechanical ventilation, thus contributing to attenuate the burden of the disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据